Drug profile · INN
istradefylline
NOURYANT
istradefylline (NOURYANT) is a adenosine a2a receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — istradefylline
- US status
- approved
- Class
- Nervous system (N04)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
istradefylline (NOURYANT) is a adenosine a2a receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adenosine A2a receptor antagonist
Primary target: Adenosine receptor A2a
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | refused | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is istradefylline?
istradefylline (NOURYANT) is a adenosine a2a receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for istradefylline?
NOURYANT is a marketed brand name for istradefylline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of istradefylline?
istradefylline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.